Retinitis Pigmentosa (Retinitis) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) – Pipeline Review, H2 2016’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)

The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Retinitis Pigmentosa (Retinitis) therapeutics and enlists all their major and minor projects

The report assesses Retinitis Pigmentosa (Retinitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acucela Inc

Allergan Plc

Amarantus Bioscience Holdings Inc

Amgen Inc

Applied Genetic Technologies Corp

Asklepios BioPharmaceutical Inc

Astellas Pharma Inc

Caladrius Biosciences Inc

Dompe Farmaceutici SpA

Genethon SA

GenSight Biologics SA

Grupo Ferrer Internacional SA

ID Pharma Co Ltd

InFlectis BioScience

Ionis Pharmaceuticals Inc

M's Science Corp

MeiraGTx Ltd

Mimetogen Pharmaceuticals Inc

Nanovector srl

Novelion Therapeutics Inc

RegenxBio Inc

ReNeuron Group Plc

SanBio Inc

Sanofi

Shire Plc

Spark Therapeutics Inc

Staidson (Beijing) Biopharmaceuticals Co Ltd

Sucampo Pharmaceuticals Inc

Sun Pharma Advanced Research Company Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Retinitis Pigmentosa (Retinitis) Overview 6

Therapeutics Development 7

Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies 9

Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes 11

Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance 12

Retinitis Pigmentosa (Retinitis) - Products under Development by Companies 15

Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes 17

Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 18

Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 47

Drug Profiles 57

Retinitis Pigmentosa (Retinitis) - Dormant Projects 138

Retinitis Pigmentosa (Retinitis) - Discontinued Products 140

Retinitis Pigmentosa (Retinitis) - Product Development Milestones 141

Appendix 156

List of Tables

List of Tables

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2016 13

Number of Products under Development for Retinitis Pigmentosa (Retinitis) – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Investigation by Universities/Institutes, H2 2016 23

Retinitis Pigmentosa (Retinitis) – Pipeline by Acucela Inc, H2 2016 24

Retinitis Pigmentosa (Retinitis) – Pipeline by Allergan Plc, H2 2016 25

Retinitis Pigmentosa (Retinitis) – Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 26

Retinitis Pigmentosa (Retinitis) – Pipeline by Amgen Inc, H2 2016 27

Retinitis Pigmentosa (Retinitis) – Pipeline by Applied Genetic Technologies Corp, H2 2016 28

Retinitis Pigmentosa (Retinitis) – Pipeline by Asklepios BioPharmaceutical Inc, H2 2016 29

Retinitis Pigmentosa (Retinitis) – Pipeline by Astellas Pharma Inc, H2 2016 30

Retinitis Pigmentosa (Retinitis) – Pipeline by Caladrius Biosciences Inc, H2 2016 31

Retinitis Pigmentosa (Retinitis) – Pipeline by Dompe Farmaceutici SpA, H2 2016 32

Retinitis Pigmentosa (Retinitis) – Pipeline by Genethon SA, H2 2016 33

Retinitis Pigmentosa (Retinitis) – Pipeline by GenSight Biologics SA, H2 2016 34

Retinitis Pigmentosa (Retinitis) – Pipeline by Grupo Ferrer Internacional SA, H2 2016 35

Retinitis Pigmentosa (Retinitis) – Pipeline by ID Pharma Co Ltd, H2 2016 36

Retinitis Pigmentosa (Retinitis) – Pipeline by InFlectis BioScience, H2 2016 37

Retinitis Pigmentosa (Retinitis) – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 38

Retinitis Pigmentosa (Retinitis) – Pipeline by M's Science Corp, H2 2016 39

Retinitis Pigmentosa (Retinitis) – Pipeline by MeiraGTx Ltd, H2 2016 40

Retinitis Pigmentosa (Retinitis) – Pipeline by Mimetogen Pharmaceuticals Inc, H2 2016 41

Retinitis Pigmentosa (Retinitis) – Pipeline by Nanovector srl, H2 2016 42

Retinitis Pigmentosa (Retinitis) – Pipeline by Novelion Therapeutics Inc, H2 2016 43

Retinitis Pigmentosa (Retinitis) – Pipeline by RegenxBio Inc, H2 2016 44

Retinitis Pigmentosa (Retinitis) – Pipeline by ReNeuron Group Plc, H2 2016 45

Retinitis Pigmentosa (Retinitis) – Pipeline by SanBio Inc, H2 2016 46

Retinitis Pigmentosa (Retinitis) – Pipeline by Sanofi, H2 2016 47

Retinitis Pigmentosa (Retinitis) – Pipeline by Shire Plc, H2 2016 48

Retinitis Pigmentosa (Retinitis) – Pipeline by Spark Therapeutics Inc, H2 2016 49

Retinitis Pigmentosa (Retinitis) – Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, H2 2016 50

Retinitis Pigmentosa (Retinitis) – Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 51

Retinitis Pigmentosa (Retinitis) – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 52

Assessment by Monotherapy Products, H2 2016 53

Number of Products by Stage and Target, H2 2016 55

Number of Products by Stage and Mechanism of Action, H2 2016 58

Number of Products by Stage and Route of Administration, H2 2016 60

Number of Products by Stage and Molecule Type, H2 2016 62

Retinitis Pigmentosa (Retinitis) – Dormant Projects, H2 2016 144

Retinitis Pigmentosa (Retinitis) – Dormant Projects (Contd..1), H2 2016 145

Retinitis Pigmentosa (Retinitis) – Discontinued Products, H2 2016 14

List of Figures

List of Figures

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2016 13

Number of Products under Development for Retinitis Pigmentosa (Retinitis) – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy Products, H2 2016 53

Number of Products by Top 10 Targets, H2 2016 54

Number of Products by Stage and Top 10 Targets, H2 2016 54

Number of Products by Top 10 Mechanism of Actions, H2 2016 57

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 57

Number of Products by Routes of Administration, H2 2016 59

Number of Products by Stage and Routes of Administration, H2 2016 59

Number of Products by Molecule Types, H2 2016 61

Number of Products by Stage and Molecule Types, H2 2016 61

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports